Evaluasi Kualitas Hidup Pasien Kanker Payudara Pengguna Kemoterapi di RSUD Provinsi NTB

Baiq Lenysia Puspita Anjani, Cyntiya Rahmawati, Nursela Hijriani

Abstract


Functional status changes may occur as side effects of chemotherapy in cancer patients, potentially reducing their quality of life. This study aimed to evaluate the quality of life of chemotherapy patients at the West Nusa Tenggara Provincial Hospital. An analytical observational method with a cross-sectional approach was used. Subjects were breast cancer patients aged ≥18 years undergoing chemotherapy. Quality of life was assessed using the FACT-G questionnaire, while demographic data and chemotherapy regimens were obtained from medical records. Data analysis included correlation tests for demographic variables and independent T-tests to compare quality of life scores across chemotherapy regimens. Results showed no significant correlation between chemotherapy regimens (TAC and AC) and variables such as age, treatment duration, occupation, education, or cancer stage (P>0.05). However, the number of treatment cycles was significantly correlated with the chemotherapy regimen (P<0.05). Patients receiving the AC regimen had higher average scores in social, emotional, and functional dimensions compared to those receiving TAC. In conclusion, there was no statistically significant difference in quality of life between the TAC and AC groups (P>0.05), though overall FACT-G scores indicated a better quality of life in patients treated with the AC regimen.


Keywords


Quality of Life Breast Cancer, FACT-G, Chemotherapy, West Nusa Tenggara Provincial Hospital

Full Text:

PDF

References


Agustini, D. D., Surahman, E., & Abdulah, R. (2015). Quality of Life Patients with Breast Cancer Therapy Combination Fluorouracil, Doxorubicin, and Cyclofosfamide. Indonesian Journal of Clinical Pharmacy, 4(3), 175–185.

Anggraini, D., Semiarty, R., Rasyid, R., & Khambri, D. (2018). Faktor-faktor yang mempengaruhi kualitas hidup penderita kanker payudara di kota Padang. Jurnal Endurance, 3(3), 562–567.

Basuki, A. R., Perwitasari, D. A., & Hardiyanto, H. (2020). Adverse Drug Reactions (ADRS) Antikanker pada Pasien Ca Mammae yang Menjalani Kemoterapi di RSUD Kota Yogyakarta. Jurnal Health Sains, 1(6), 349–359.

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424.

Colombo, R., Doherty, D. J., Wilson, C. M., Krzys, K., Lange, S., & Maynes, H. (2018). Implementation and preliminary analysis of FACT-G quality of life questionnaire within an oncology survivorship clinic. Cureus, 10(3).

Desen, W. (2013). Kemoterapi Tumor Ganas Buku Ajar Onkologi Klinis (II). Balai Penerbit FKUI.

Gradishar, W. J., Moran, M. S., Abraham, J., Aft, R., Agnese, D., Allison, K. H., … Elias, A. D. (2021). NCCN guidelines® insights: breast cancer, version 4.2021: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network, 19(5), 484–493.

Husni, M., Romadoni, S., & Rukiyati, D. (2015). Hubungan dukungan keluarga dengan kualitas hidup pasien kanker payudara di instalasi rawat inap bedah RSUP Dr. Mohammad Hoesin Palembang Tahun 2012. Jurnal Keperawatan Sriwijaya, 2(2), 77–83.

Irawan, E., Hayati, S., & Purwaningsih, D. (2017). Hubungan dukungan keluarga dengan kualitas hidup penderita kanker payudara. Jurnal Keperawatan BSI, 5(2).

Kang, Y.-K., Si, Y.-R., An, G.-Y., & Yuan, P. (2021). Efficacy and safety of cyclophosphamide in anthracycline-and taxane-based neoadjuvant chemotherapy in breast cancer: a meta-analysis. Gland Surgery, 10(1), 252.

Kartikawati, E. (2013). Awas. Bahaya Kanker Payudara Dan Kanker Serviks. Bandung: Buku Baru.

Meregaglia, M., Borsoi, L., Cairns, J., & Tarricone, R. (2019). Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia. The European Journal of Health Economics, 20(2), 181–193.

Oh, H.-J. S., Menéndez, Á. F., Santos, V. S., Martínez, Á. R., Ribeiro, F. F., Vilanova-Trillo, L., … Ferreiros, M. P. (2021). Evaluating health related quality of life in outpatients receiving anti-cancer treatment: results from an observational, cross-sectional study. Health and Quality of Life Outcomes, 19(1), 1–8.

Pangribowo, S. (2019). Beban Kanker di Indonesia. Pusat Data Dan Informasi Kesehatan Kementerian Kesehatan RI, 1–16.

Prayoga, A. A. (2019). Manajemen Kanker Payudara Komprehensif. Airlangga University Press.

Ratna, R., Supadmi, W., & Yuniarti, E. (2021). Kualitas Hidup Pasien Kanker Rawat Jalan yang Menjalani Kemoterapi di RSUD Kota Yogyakarta. Majalah Farmaseutik, 17(2), 278–286.

Sistem Informasi Manajemen RSUD Provinsi NTB. (2023). Pasien Kanker Payudara di RSUD Provinsi NTB. Mataram.

Sitlinger, A., & Zafar, S. Y. (2018). Health-related quality of life: the impact on morbidity and mortality. Surgical Oncology Clinics, 27(4), 675–684.

Suanjaya, M. A., Sherliyanah, S., & Utami, S. (2021). Prevalence and Characteristics of Breast Cancer Patients in Mataram City for the 2015-2020 Period. Jurnal Aisyah: Jurnal Ilmu Kesehatan, 6(2), 403–408.

Sukma, A. A. M., Yuliyanasari, N., Prijambodo, T., & Primadina, N. (2020). Pengaruh Siklus Kemoterapi terhadap Kualitas Hidup Pasien Kanker Payudara Menggunakan Eortc Qlq-C30 di RSUD Dr. Soetomo Surabaya. Jurnal Implementa Husada, 1(2), 117–125.

Van Rossum, A. G. J., Kok, M., van Werkhoven, E., Opdam, M., Mandjes, I. A. M., van Leeuwen–Stok, A. E., … Bos, M. (2018). Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04). European Journal of Cancer, 102, 40–48.

Yuniarti, E., Supadmi, W., Wahyuni, F. A., & Ratna, R. (2021). Kualitas Hidup Pasien Kanker yang Menjalani Kemoterapi di Rumah Sakit Yogyakarta. In Prosiding University Research Colloquium (pp. 594–606).




DOI: https://doi.org/10.31764/lf.v6i2.32528

Refbacks

  • There are currently no refbacks.


EDITORIAL OFFICE: